The way I see it, the results would be good and then there will either be a CR or a deal with a cornerstone investor. More likely to be the latter.
And since it is a 'short-term trial read-outs', my bet is on data readout from either the Vaxinia bile duct or OnCarlytic/Blincyto trial. Again, I suspect the latter and thereby the cornerstone investor could well be Amgen.
Above just my speculation.
Media Thread, page-15022
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
